Results 71 to 80 of about 10,491 (187)

A Review on Medicinal Chemistry and Biological Activity of Dihydropyrimidinones Against HIV

Archiv der Pharmazie, Volume 359, Issue 4, April 2026.
This article presents the latest advances in the development of dihydropyrimidinone (DHPM) derivatives as promising candidates against HIV. By exploring their interactions with essential viral targets and highlighting innovative compounds with potent antiviral activity, we provide an updated perspective on the opportunities for new antiretroviral ...
Debora I. Leite, Fernando B. Macedo, Murilo Marinho de C. Lima, Isabelle S. Brum, Jonathan Fragoso Miranda de Oliveira, Ana Clara S. Costa, Stella C. Duarte, Sarah Moon, Stefany de Castro B. Moura, Andressa P. de Oliveira, Nubia Boechat, Monica M. Bastos   +11 more
wiley   +1 more source

Raltegravir: Its use in the Treatment of HIV Infection

, 2009
Raltegravir is the first integrase strand transfer inhibitor to be approved for the treatment of HIV infection. Administered orally in doses of 400 mg twice daily, it is well-tolerated and has minimal drug-drug interactions with coadministered ...
Marianne Harris
core   +2 more sources

Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen

Clinical Epidemiology, 2010
Frederik N Engsig1, Jan Gerstoft1, Gitte Kronborg2, Carsten S Larsen3, Gitte Pedersen4, Anne M Audelin5, Louise B Jørgensen5, Niels Obel11Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Denmark; 2Department ...
Frederik N Engsig, Jan Gerstoft, Gitte Kronborg, et al   +3 more
doaj  

Effectiveness and Persistence of Long‐Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY Cohort

Journal of the International AIDS Society, Volume 29, Issue 4, April 2026.
ABSTRACT Introduction Migrants living with HIV often face high mobility, vulnerability and limited baseline information on HIV‐1 genotype or treatment history. We aimed to assess the effectiveness and persistence of long‐acting injectable cabotegravir and rilpivirine (LAI CAB+RPV) among migrants in Spain. Methods This multicentre cohort study across 58
Jara Llenas‐García, María del Mar Arcos Rueda, Ruth Calderón Hernaiz, Roberto Pedrero Tomé, Otilia Bisbal Pardo, Mariano Matarranz, Miguel Torralba, María José Galindo Puerto, Adrián Rodríguez, María Peñaranda Vera, Isabel Sanjoaquín Conde, Sara de la Fuente Moral, Alfonso Cabello‑Úbeda, Carolina Navarro San Francisco, Karenina Antelo Cuéllar, Marc Pedrosa Aragón, María Aguilera García, Juan Tiraboschi, Rosa María Martínez Álvarez, María Jesús Vivancos, Carmen Montero Hernández, Enrique Bernal Morell, Noemí Cabello‐Clotet, Luis Enrique Morano Amado, Laura Gisbert Pérez, María Antonia Sepúlveda, María Remedios Alemán Valls, Antonio Jesús Sánchez Guirao, Chiara Fanciulli, Cristina Escrig, Eva María Ferreira Pasos, Ana Lucas‐Dato, Sara García Torras, Carmen Hidalgo Tenorio, Miriam Estébanez, Magdalena Muelas‑Fernandez, Juan Emilio Losa García, Ana Cerezales Calviño, María Elisa Pino Díaz, Clara Martínez Montes, Víctor Arenas García, Francisco Arnaiz de las Revillas, Hadrián Pernas Pardavila, Sergio Padilla, María Ángeles Garcinuño Jiménez, Lucía Alonso Alonso, Noemí Ramos Vicente, Patricia Noemí Barragán Gallo, Rebeca Cabo Magadan, Míkel del Álamo, Miguel Vicente Egido Murciano, Alberto Juárez Toquero, Alberto Romero Palacios, Marta Clavero Olmos, María del Mar García Navarro, José Sanz, Juan Carlos Gainzarain, Marta Milian Sanz, Beatriz de la Calle, Oscar Luis Ferrero Benéitez, Jesús Troya, Luis Buzón‐Martín, The RELATIVITY Group   +62 more
wiley   +1 more source

HIV resistance to raltegravir

, 2009
Similar to all antiretroviral drugs, failure of raltegravirbased treatment regimens to fully supress HIV replication almost invariably results in emergence of HIV resistance to this new drug.
Clavel, François, Clavel François
core   +1 more source

Raltegravir: molecular basis of its mechanism of action

European Journal of Medical Research, 2009
Integration of the HIV-1 viral DNA generated by reverse transcription of the RNA genome into the host cell chromosomes is a key step of viral replication, catalyzed by the viral integrase.
Mouscadet Jean-François, Tchertanov Luba   +1 more
doaj   +1 more source

Drug-drug interactions between raltegravir and pravastatin in healthy volunteers.

, 2010
Contains fulltext : 88810.pdf (Publisher’s version ) (Open Access)BACKGROUND: To evaluate the potential drug-drug interaction between raltegravir and pravastatin. METHODS: This was an open-label, randomized, 3-period, cross-over, single-
Burger, D.M., Schouwenberg, B.J.J.W., Luin, M. van, Silva, H.G. da, Ewijk-Beneken Kolmer, E.W.J. van, Verwey-van Wissen, C.P.W.G.M., Colbers, A., Hoitsma, A.J.   +7 more
core   +1 more source

Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence

Viruses, 2015
Drug resistance prevents the successful treatment of HIV-positive individuals by decreasing viral sensitivity to a drug or a class of drugs. In addition to transmitted resistant viruses, treatment-naïve individuals can be confronted with the problem of ...
Thibault Mesplède, Mark A. Wainberg
doaj   +1 more source

Raltegravir use in special populations

, 2009
Raltegravir, the first approved integrase inhibitor, has been shown to be virologically effective in Phase II and Phase III clinical trials in both treatment naïve and triple class resistant patients.
Johnson Margaret
core   +1 more source

Raltegravir with optimized background therapy for resistant HIV-1 infection.

, 2008
peer reviewedBACKGROUND: Raltegravir (MK-0518) is an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase active against HIV-1 susceptible or resistant to older antiretroviral drugs.
KUMAR PN, LOUTFY, Nguyen, Bach-Yen, Rhodes, Rand R, Nessly, Michael L, MEIBOHM, AR, MILLER MD, Katlama, Christine, Clotet, Bonaventura, RHODES RR, FILICE, GAETANO, SCHECHTER M, CHEN J, Isaacs, Robin D., BENCHMRK STUDY TEAMS, Lennox, Jeffrey L., Gilde, Lucinda R, Hazuda, Daria J., Lennox, Jeffrey L, Isaacs, Robin D, Strohmaier, Kim M., Miller, Michael D, VULLO, Vincenzo, RYAN DM, Loutfy MR, Lazzarin, Adriano, Strohmaier, Kim M, Meibohm, Anne R, MARKOWITZ M, Eron, Joseph E., Schechter, Mauro, Miller, Michael D., Killar, John A, ZHAO J, Loutfy, Mona R., NESSLY ML, Cooper, David A, GILDE LR, Chen, Joshua, LAZZARIN A, Meibohm, Anne R., Gatell, Jose M., Rockstroh, Jurgen K, GATELL JM, DINUBILE MJ, TEPPLER H, STEIGBIGEL RT, Kumar, Princy N., DiNubile, Mark J., Steigbigel, Roy T, NGUYEN BY, LENNOX JL, COOPER DA, Meibohm AR, KATLAMA C, CLOTET B, Hazuda, Daria J, Rockstroh, Jurgen K., Markowitz, Martin, HAZUDA DJ, Rhodes, Rand R., Gatell, Jose M, Steigbigel, Roy T., Cooper, David A., Kumar, Princy N, ISAACS RD, Yeni, Patrick, Ryan, Desmond M., YENI P, ROCKSTROH JK, STROHMAIER KM, Nessly, Michael L., KILLAR JA, Eron, Joseph E, Gilde, Lucinda R., Loutfy, Mona R, Teppler, Hedy, Zhao, Jing, ERON JE, Ryan, Desmond M, DiNubile, Mark J, Killar, John A.   +81 more
core   +1 more source